443 related articles for article (PubMed ID: 25474320)
21. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
22. Nintedanib: first global approval.
McCormack PL
Drugs; 2015 Jan; 75(1):129-39. PubMed ID: 25430078
[TBL] [Abstract][Full Text] [Related]
23. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
Fukihara J; Kondoh Y
Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
[TBL] [Abstract][Full Text] [Related]
24. The potential role of nintedanib in treating colorectal cancer.
Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
[TBL] [Abstract][Full Text] [Related]
25. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Capdevila J; Carrato A; Tabernero J; Grande E
Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
[TBL] [Abstract][Full Text] [Related]
28. Nintedanib in idiopathic pulmonary fibrosis.
Woodcock HV; Maher TM
Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
[TBL] [Abstract][Full Text] [Related]
29. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
30. Nintedanib - efficacy, safety and practical aspects of treatment for patients with idiopathic pulmonary fibrosis.
Martusewicz-Boros M; Górska K
Adv Respir Med; 2020; 88(6):599-607. PubMed ID: 33393653
[TBL] [Abstract][Full Text] [Related]
31. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Liu F; Bayliss G; Zhuang S
Clin Sci (Lond); 2019 Jun; 133(12):1309-1320. PubMed ID: 31217321
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Schmid U; Doege C; Dallinger C; Freiwald M
Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
[TBL] [Abstract][Full Text] [Related]
33. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
34. The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications.
Grześk G; Woźniak-Wiśniewska A; Błażejewski J; Górny B; Wołowiec Ł; Rogowicz D; Nowaczyk A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396592
[TBL] [Abstract][Full Text] [Related]
35. Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy.
Landi C; Bergantini L; Cameli P; d'Alessandro M; Carleo A; Shaba E; Rottoli P; Bini L; Bargagli E
Sci Rep; 2020 Jun; 10(1):9378. PubMed ID: 32523095
[TBL] [Abstract][Full Text] [Related]
36. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor.
Reck M
Expert Rev Anticancer Ther; 2015 May; 15(5):579-94. PubMed ID: 25831142
[TBL] [Abstract][Full Text] [Related]
38. Is nintedanib effective for idiopathic pulmonary fibrosis?
Jeldres A; Labarca G
Medwave; 2017 Apr; 17(Suppl2):e6918. PubMed ID: 28430774
[TBL] [Abstract][Full Text] [Related]
39. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Cottin V
Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
[TBL] [Abstract][Full Text] [Related]
40. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]